ࡱ> z|yq` RbjbjqPqPh::%" " " " B B B V bbb8D4V O&"@@@555NNNNNNN$@RhT@N-B "@5""N" " @@N&&&"" @@B @N&"N&&MI0b B L@ (HXbP%}J$EM<N0OJU%UHLUB L5&w l 555NN&^555O""""V V d >$V V >V V V " " " " " "  Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limited(a joint stock company established in the People s Republic of China with limited liability)(Stock Code: 0719)APPOINTMENT OF DIRECTORSThe Board announces that with effect from 20 September 2010, Mr. Zhang Daiming and Mr. Du Deping have been appointed as executive directors of the Company.The board of directors (the Board) of Shandong Xinhua Pharmaceutical Company Limited (the Company) announces that with effect from 20 September 2010, Mr. Zhang Daiming (Mr. Zhang) and Mr. Du Deping (Mr. Du) have been appointed as executive directors of the Company.Mr. Zhang Daiming, aged 48, is a senior economist. He graduated from Qingdao Science and Technology University, specialising in organic chemical engineering and obtained a masters degree in economics from Shanghai Financial and Economic University. Mr. Zhang joined Shangdong Xinhua Pharmaceutical Factory in 1987 and was previously workshop technician, planner of the planning and statistics department of the Company, the deputy manager and manager of international trade department of the Company and the deputy general manager of the Company. Mr. Zhang is the chairman of the board of Shandong Xinhua Pharmaceutical Group Company Limited, Shandong Xinhua Import and Export Company Limited and Shandong Xinhua Pharmaceutical (Europe) GmbH, and a director of Shandong Xinhua Medical Trade Company Limited, Zibo Xinhua Eastwest Pharmaceutical Company Limited and Zibo Xinhua- Perrigo Pharmaceutical Company Limited.Save as disclosed above, Mr. Zhang :-did not hold any other directorship in any listed companies in the past three years or any positions with the Company or other members of the Group; has no relationship with any directors, senior management or substantial or controlling shareholders of the Company; anddoes not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) at the date hereof.Mr. Zhang has not entered into any service contract with the Company. The Board has been authorised to fix Mr. Zhangs emolument for 2010 which will be determined by reference to his experience and the emoluments of other executive directors of the Company. An announcement will be made when Mr. Zhangs emolument for 2010 is fixed. The term of office of Mr. Zhang commences from 20 September 2010 and will end on the expiry of the term of the sixth Board of the Company.Further, there is nothing in respect of Mr. Zhang which needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Ltd (the Listing Rules) nor is there anything that needs to be brought to the attention of the shareholders of the Company.The Board takes this opportunity to welcome Mr. Zhang to join the Board.Mr. Du Deping, aged 41, is a senior engineer. He graduated from the Ocean University of PRC, specialising in chemistry and obtained a masters degree in medicinal chemistry from Shandong University. He joined Shandong Xinhua Pharmaceutical Factory in 1991. He was previously a deputy head and head of the workshop, assistant to the general manager of the Company and deputy general manager of the Company. Mr. Du is currently the general manager of the Company, and the chairman of the board of Zibo Xinhua Pharmaceutical Design Institute Company Limited and Xinhua Pharmaceutical (Shouguang) Company Limited.Save as disclosed above, Mr. Du :-did not hold any other directorship in any listed companies in the past three years or any positions with the Company or other members of the Group; has no relationship with any directors, senior management or substantial or controlling shareholders of the Company; anddoes not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) at the date hereof.Mr. Du has not entered into any service contract with the Company. The Board has been authorised to fix Mr. Dus emolument for 2010 which will be determined by reference to his experience and the emoluments of other executive directors of the Company. An announcement will be made when Mr. Dus emolument for 2010 is fixed. The term of office of Mr. Du commences from 20 September 2010 and will end on the expiry of the term of the sixth Board of the Company.Further, there is nothing in respect of Mr. Du which needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules nor is there anything that needs to be brought to the attention of the shareholders of the Company.The Board takes this opportunity to welcome Mr. Du to join the Board. By Order of the Board Shandong Xinhua Pharmaceutical Company Limited Zhang Daiming Chairman20 September 2010, Zibo, PRCAs at the date of this announcement, the Board comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Ren FulongMr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Sun MinggaoMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Xu LieMr. Zhao BinPAGE PAGE 3q r s  x 0 2 V X Z оt[I3. ho(+hB*CJKHOJQJaJmH phsH #hB*KHOJQJmH ph# sH 1h6B*CJKHOJQJ]aJmH ph# sH @h6B*CJKHOJPJQJ]aJmH nHo(ph# sH tH1h6B*CJKHOJQJ]aJmH ph# sH  hKHh5PJ\o(#h5PJ\mH nHo(sH tH+jh5PJU\mHnHo(tHu haJhjhUaJmHnHur t u v  x 2 X Z d e $$7$8$G$H$Ifa$ $7$8$H$a$ $3$a$ $7$8$H$a$N ؝1$3$N ؝1$3$G$SxZ     ( + - R S e g ӸxxkxxhKHaJmH o(sH %hKHPJaJmH nHo(sH tH"hKHPJaJmH nHsH tHh5KH\aJmH sH hKHaJmH sH hKHmH sH !hKHPJmH nHo(sH tHhKHmH o(sH hKHOJQJmH sH h;PJnHo(tH h;o($e f g yz7Fwww $ & F7$8$H$a$ $7$8$H$a$gd* $7$8$H$a$ $7$8$G$H$a$[kd$$If5$$064 a!45;<>@Bghwxyzn/3ae.3GʷݘzgzgzgzgZgzZzZz݆h*KHaJmH o(sH %h*KHPJaJmH nHo(sH tHh*KHaJmH sH "hKHPJaJmH nHsH tHhKHmH sH (h5KHPJaJmH nHo(sH tH%h5KHPJaJmH nHsH tH%hKHPJaJmH nHo(sH tHhKHaJmH sH +h5KHPJ\aJmH nHo(sH tH#GJPS<jkmv#$C]bklrtu~EJ]_0N  +-1⦓%hxKHPJaJmH nHo(sH tH%hMKHPJaJmH nHo(sH tH+h5KHPJ\aJmH nHo(sH tH%hKHPJaJmH nHo(sH tHhKHaJmH sH "hKHPJaJmH nHsH tH5^_{pqZ[~!Z$6%3$G$ $3$G$a$ $7$8$G$H$a$ $ & F7$8$H$a$ $7$8$H$a$1@JNq5| #%&鴤ssssss"hKHPJaJmH nHsH tH%hKHPJaJmH nHo(sH tHhKHaJmH sH h5hKHaJmH o(sH h5hKHaJmH sH +h5h+8'KHPJaJmH nHo(sH tHh5h+8'KHaJmH o(sH +h5hMKHPJaJmH nHo(sH tH-&6n [\qwgaThKHPJnHo(tH hKHhB*CJOJPJaJph#hB*OJPJaJnHphtHhPJnHo(tH h6hPJ\nHo(tHh5PJ\nHo(tH h5\ h5hhKHmH sH hKHaJmH sH "hKHPJaJmH nHsH tH%hKHPJaJmH nHo(sH tH [\q8CGkd$$If0!64 a $7$8$H$If$a$$3$G$a$8<BCGOPRSTVWYZ\]_`fghjkqrstuvwxӫwphCJo(hnHo(tHh8l0JmHnHuh h0Jjh0JUh0jh0UhKHaJh8lKHPJnHo(tH h8lKHhKHPJnHo(tH hKHhDhKHhDKHPJnHo(tHhDhKHPJnHo(tH,CPQRSUVXY[\^_hiju&`#$ $7$8$H$a$Gkd$$If0!64 a $7$8$H$Ifuvwxyz{|}~ $7$8$H$a$ $4$a$gd_+hKHaJ8&P 1h2PP. A!"#$% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBK00}03g2 K00Trtuv"#<=>Ck l D E 78[j/_nx!23Xhx000000000 00#0#0#0#0#0#0#0#0#0#0# 0# 0# 0#0#0#0#0#0#0#0#0#0#0# 0# 0# 0#0#0#0#0#0#0#0#0#0#0#X00r0r0r0r0r0r0r0r0r0r 0r0r0r0r0r 0r 0r0r0r 0r 0r 0@0I00@0I00@0I00@0I00@0@0@0@0@0@0I0000000000000000000000000|X E 7K00\K00K000qK00K00K00 I00I00I00K00K003K00 30K00`  $$$'Z G1&e Cu  '!!l,b$l?xK-}*:>@8(  H  # N  S AB S  ?r$(t(\tNNBN/NNtBN<N|NtNNN4NNܺIT    S^  8*urn:schemas-microsoft-com:office:smarttagsCity= *urn:schemas-microsoft-com:office:smarttags PlaceType= *urn:schemas-microsoft-com:office:smarttags PlaceNameB*urn:schemas-microsoft-com:office:smarttagscountry-region9 *urn:schemas-microsoft-com:office:smarttagsplace 8W v5<`l GM}$%-V\^e oq $UW pz<@xz9?fm   *1`gpw|vUYKM3333#=`ox13XQ*.7/S dWe$(jD^ߎB\* Gp^$4ZbF-RҨLHN S %Z^oRa6bJE dŚ utXhh^h`o(.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH. @^`@o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .u?u^u`?o(.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH.?^`?o(?^`?o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o(...... `^``o(....... ^`o(........ ?^`?B*o(ph.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH.  ^` o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` . ^` o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .hh^h`o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .0^`0o(() ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` . @^`@5o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .  ^` o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .0^`0PJo(() H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.  ^` o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .  ^` o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` . ^`o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .WQ^\*  utE dBRa7/S LH Sp^$F-%Z^        v>T[                ڤO        p@B        2ZJ        B:T                Fg3         8        Vj        @         Z)        `        Q2M+8'_+,0 A9BSCDtH>YZD:eA"g-wq*pe8lE15}-x B#O#=7nx3S+0S+0S+0S+0S+0S+0S+0S+0S+0S+0@x(vv@ @Unknown Gz Times New Roman5Symbol3& z Arial;[SOSimSunC .PMingLiUe0}fԚaTimes-ItalicTimes New Roman_ Times-RomanTimes New RomanKE  .DFKai-SBPMingLiU?5 .MingLiU0}fԚU Arial Unicode MSArialKPMCHM I+ Times[SO 1hsF& sF@ '@ '!?!),.:;?]}    " % & ' 2 t%00 0 000000013468:<>@BDOPQRTUVWZ\^ \]d([{  5 0 0 00000579;=?ACY[][d2qHX?>Y2~The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation Charltons_o(u7bH          Oh+'0(4HT`t    The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation Charltons Normal.dot ΢û19Microsoft Office Word@ԭ@`S@6]%S@)/X@՜.+,0 X`t|  Charltons'    !"#$%&'()*+,-./012346789:;<>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghjklmnoprstuvwx{Root Entry FHX}Data 51Table=0VWordDocumenthSummaryInformation(iDocumentSummaryInformation8qCompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q